ESTRO 2023 - Abstract Book

S1076

Digital Posters

ESTRO 2023

Conclusion IORTE treatment in patients with resected pancreatic cancer is an effective, safe, and well-tolerated treatment that should be taken into account in multidisciplinary committees.

PO-1344 Prognostic significance of platelet-to-lymphocyte ratio in hepatocellular carcinoma

D.S. Lee 1

1 College of Medicine, The Catholic University of Korea, Department of Radiation Oncology, Seoul, Korea Republic of

Purpose or Objective Growing evidences support that elevated platelet-to-lymphocyte ratio (PLR) is associated with poor clinical outcomes in human cancer and distant metastasis (DM) is the major contributor to the devastating prognosis. We aimed to investigate whether serum inflammatory parameters can help to predict the clinical outcomes in patients with unresectable hepatocellular carcinoma (HCC) undergoing curative radiation therapy (RT). Materials and Methods A total of 76 RT courses among 71 patients were analyzed. The following variables were included in the analysis: systemic inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), prognostic nutritional index, absolute lymphocyte count, lymphocyte-to-monocyte ratio, albumin, albumin-to-alkaline phosphatase ratio, RT-related parameters, and levels of total protein, hemoglobin, α -fetoprotein, and PIVKA-II. The Kaplan–Meier method was used for survival analysis, and survival graphs were compared using the log-rank test. The multivariate Cox proportional hazards model was adapted to assess the prognostic significance. Overall survival (OS) and distant control (DC) rates were calculated and compared. Results The mean age was 61.4 years, and most patients were men (n = 62, 81.6%). Most of the study population underwent pre RT TACE/HAIC (n = 74, 97.4%). The median RT fraction number, fractional doses, and biologically equivalent doses by α / β =10 were 12 (range, 4–30), 5 (range, 2–12) Gy and 72.6 (range, 51.5–119) Gy, respectively. With a median follow-up of 12 (range, 3.1–56.7) months, the 1-year OS and DC rates were 55.2% and 64.4%, respectively. Development of DM significantly deteriorated OS rates (P = 0.011), while local (P = 0.690) and intrahepatic recurrences (P = 0.102) did not. In the multivariate analysis for DC rates, significant independent prognostic indicator was the highest posttreatment PLR ( ≤ 235.7 vs. > 235.7, P = 0.006). Conclusion Posttreatment serum PLR might be used as a distinctive predictive biomarker of DC rates in unresectable HCC undergoing RT. Future research is necessary to confirm our findings.